Table 2 Demographic characteristics of included participants
From: Gout is not associated with the risk of fracture: a meta-analysis
Author | Year | Female, n (%) | Mean age, years | Mean duration of follow-up, years | Comorbidities | |||
|---|---|---|---|---|---|---|---|---|
Gout group | Control group | Gout group | Control group | Gout group | Control group | |||
Tzeng, et al. [23] | 2016 | 13,142 (30.1) | 26,284 (30.1) | 50.9 ± 16.0 | 50.9 ± 16.0 | 11 | 11 | ALD, CAD, COPD, DM, ESRD, hypertension, osteoporosis, parkinson disease, stroke |
Kim, et al. [25] | 2017 | 13,176 (18.0) | 39,529 (18.0) | 60.0 ± 7.5 | 60.0 ± 7.5 | 2.0 ± 1.7 | 2.0 ± 1.8 | Hypertension, stroke, cardiovascular disease, bone mineral density testing ordered, osteoporosis, dementia, chronic lung disease, chronic kidney disease, CAD, hyperlipidemia, obesity, DM, smoking, alcoholism, comorbidity score |
Paik, et al. [17] | 2017 | 2225 (100) | 101,574 (100) | 59.6 ± 6.5 | 56.0 ± 7.1 | 14 for the wrist fracture analysis; 22 for the hip fracture analysis | 14 for the wrist fracture analysis; 22 the hip fracture analysis | Current smokers, hypertension, DM, osteoporosis, taking a thiazide diuretic |
Sultan, et al. [1] | 2018 | 8601 (17.1) | 32,983 (16.8) | 63.5 ± 12.5 | 63.1 ± 12.2 | 10.8 (6.7–13.4)* | 10.8 (6.8–13.6)* | Smoking, alcohol consumption, history of falls, antihypertensive agents, antidiabetic agents, opioids, glucocorticoids, proton pump inhibitors, selective serotonin reuptake inhibitors, and bisphosphonates |
Wang, et al. [24] | 2018 | 75 (51.0) | 1646 (65.1) | 73.6 ± 12.0 | 75.6 ± 12.3 | Not mentioned | Not mentioned | Rheumatic arthritis, CAD, hypertension, DM, physical activity, alcohol, smoking |